Kokilaben Hospital Launches Mumbai’s First In-House Genomic Cancer Test

This is the first time a Mumbai hospital offers a fully integrated, end-to-end genomic testing and treatment solution within its facility.

Kokilaben Dhirubhai Ambani Hospital, Mumbai, has launched OncoKH 500 PLUS, an in-house precision oncology platform capable of profiling over 500 cancer-associated genes in a single test.

This is the first time a Mumbai hospital offers a fully integrated, end-to-end genomic testing and treatment solution within its facility.

The OncoKH 500 PLUS test is designed to detect a broad spectrum of genomic alterations, including driver mutations, gene fusions, copy number variations (CNVs), tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD). The platform supports oncologists in making more accurate and timely treatment decisions, especially for patients with advanced or metastatic cancers.

“At Kokilaben Hospital, we have built an ecosystem that mirrors the best global standards in oncology,” said Dr. Santosh Shetty, Executive Director & CEO, Kokilaben Hospital. “With the launch of OncoKH 500 PLUS, we are taking precision oncology a step further by ensuring that every cancer patient has access to genetic insights that can transform their treatment outcomes. This is not just a test, it is a gateway to world-class, personalised cancer care delivered in India.”

As the testing is conducted in-house, the process eliminates the need to send patient samples to external labs. This significantly reduces both the turnaround time for results and the anxiety associated with delayed diagnoses. A single biopsy is sufficient to deliver a high-accuracy, comprehensive report that can inform decisions on targeted therapies or immunotherapy when applicable.

Dr. Amrit Kaur Kaler, Consultant, Molecular Pathology, stated, “Every cancer behaves differently, and many patients do not respond to standard chemotherapy due to hidden resistance mutations. This test lets us decode the tumor’s genetic makeup from actionable mutations to resistance markers to personalize treatment from day one. In the first month, we have seen remarkable results and a strong response from Indian and international patients.”

The hospital reports that initial usage of the OncoKH 500 PLUS platform has seen positive engagement from oncologists and patients alike, especially in cases where personalised treatment strategies are critical.

Stay tuned for more such updates on Digital Health News